SWOG clinical trial number
CTSU/NRG-LU003

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Open
Abbreviated Title
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Activated
04/01/2019

Research committees

Lung Cancer

Treatment

Cisplatin Carboplatin Pemetrexed Crizotinib Alectinib Brigatinib Ceritinib Ensartinib Lorlatinib

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
S1914
SWOG Clinical Trial Number
S1900B